—COO
— • —
$71.21
P/E
35.25
PEG
—
FCF Yield
—
Rev Growth YoY
+569.0% YoY
Gross Margin
6544.0%
Health Score
5/10
D/E Ratio
0.30
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this payload, which limits full company identification. Based on available data, this appears to be a company trading at $71.21 per share with a P/E of 35.25x and a Price/Sales of 3.35x, suggesting a mid-sized business with moderate revenue scale. Without a confirmed market capitalisation figure, the cap tier cannot be reliably classified, though the valuation ratios are consistent with a small-to-mid cap profile.
Financial Health
**Score: 5/10** The balance sheet shows a conservative debt position with a Debt/Equity ratio of 0.3x, well within manageable territory. The gross margin of 6,544% and net margin of 967% are extraordinarily elevated figures that likely reflect an unusual accounting period or a very small revenue base, making them difficult to interpret with confidence at face value...
Risk Assessment
- **EARNINGS DETERIORATION:** Earnings growth of -236.0% YoY signals a sharp reversal in profitability despite strong headline revenue growth — a direct contradiction that warrants scrutiny. - **VALUATION PREMIUM:** P/E of 35.25x is approximately 41% above the sector average of 25x, with no PEG or DCF anchor to justify the premium. - **CASH FLOW OPACITY:** Free Cash Flow is unavailable, making it impossible to verify whether earnings quality is genuine or distorted by non-cash items. - **TECHNICAL DETERIORATION:** A confirmed death cross (50-day MA crossing below 200-day MA) with a bearish MACD signal indicates negative price momentum across multiple timeframes. - **DATA COMPLETENESS:** Missing TTM Revenue, TTM Net Income, market cap, 52-week range, and RSI limit the depth of analysis and increase uncertainty for any investment decision. ---...